Zogenix,
Inc. ZGNX and
DURECT Corporation DRRX announced today a development and license
agreement. Under the agreement, Zogenix will be responsible for the clinical
development and commercialization of a proprietary, long-acting injectable
formulation of risperidone using DURECT's SABE controlled-release
formulation technology in combination with Zogenix's DosePro needle-free,
subcutaneous drug delivery system.
The Companies will also share non-clinical
development responsibilities. Zogenix expects to initiate clinical studies for
the new product candidate, Relday, in patients with schizophrenia in early
2012 following filing of an Investigational New Drug application.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in